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Abstract
Introduction: Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease. Typical features of AD include memory 
loss, social dysfunction, and physical impairment. Although the pathological findings in the central nervous system are well established, 
the aetiological factors are poorly known. Recent studies suggested the role of metabolic disturbances in the development of AD neuro-
degeneration. Adiponectin, an anti-inflammatory and metabolism regulating factor, was linked to AD.
The aim was to examine whether adiponectin fractions combined with insulin/insulin resistance-associated metabolic parameters cor-
relate with AD progression.
Material and methods: The study comprised 98 women: 27 with moderate to severe AD, 31 with AD at early stage, and 40 healthy con-
trols, matched for age and BMI. To evaluate memory impairment, the Mini-Mental State Examination (MMSE) was performed. Plasma 
total adiponectin and its high, medium, and low molecular weights were measured with ELISA. Anthropometric, clinical, and metabolic 
parameters were assessed. Correlations between adiponectin array and measured parameters were evaluated.
Results: In comparison to the controls, enhanced levels of total and medium molecular weight adiponectin characterised AD individu-
als. In AD, we found correlations between adiponectin array, and anthropometric and biochemical parameters. After adjustment to BMI, 
a significant increase of the total adiponectin and high and medium molecular weight fractions was observed. A negative correlation 
between low molecular weight adiponectin and MMSE was found. 
Conclusions: Our results indicate a possible link between adiponectin variations and AD. We hypothesise that changes in adiponectin 
profile observed in AD result from compensatory mechanisms against neuropathological processes, as well as from adiponectin homeo-
stasis impairment. (Endokrynol Pol 2018; 69 (5): 550–559)
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Streszczenie
Wstęp: Choroba Alzheimera (AD) to postępujące, nieodwracalne schorzenie neurodegeneracyjne. Typowe cechy AD to zaburzenia pamię-
ci, dysfunkcje społeczne oraz niepełnosprawność fizyczna. Mimo że zmiany patologiczne w centralnym układzie nerwowym są dobrze 
poznane, nadal nie przedstawiono wszystkich czynników etiologicznych. Ostatnie badania wskazują na role zaburzeń metabolicznych 
w rozwoju procesów neurodegeneracyjnych w AD. Adiponektyna, będąca czynnikiem przeciwzapalnym i regulującym metabolizm, 
została powiązana z AD.
Celem pracy było określenie, czy frakcje adiponektyny w powiązaniu z insuliną i parametrami metabolicznymi zależnymi od insulino-
oporności korelują z progresją choroby Alzheimera.
Materiał i metody: Badaniem objęto 98 kobiet: 27 z AD w stadium co najmniej średnio zaawansowanym, 31 w początkowym stadium 
choroby i 40 zdrowych, dobranych pod względem wieku i BMI. Do oceny zaburzeń funkcji poznawczych użyto badania Mini-Mental State 
Examination (MMSE). W osoczu metodą ELISA określano stężenie adiponektyny całkowitej i jej frakcji. Badano także wybrane parametry 
antropometryczne, kliniczne i metaboliczne. Oceniano korelacje między profilem adiponektyny a badanymi zmiennymi.
Wyniki: W porównaniu z osobami z grupy kontrolnej w AD stwierdzono podwyższone wartości adiponektyny całkowitej i frakcji MMW. 
W grupie AD wykazano korelacje między profilem adiponektyny a parametrami antropometrycznymi i biochemicznymi. Po wyłączeniu 
BMI jako czynnika zakłócającego obserwowano wyższe stężenia adiponektyny całkowitej oraz frakcji HMW i MMW. Stwierdzono ujemną 
korelację między frakcją LMW a wynikiem MMSE. 
Wnioski: Uzyskane wyniki wskazują na możliwość obecności związku między zmianami stężeń frakcji adiponektyny a chorobą Al-
zheimera. Autorzy niniejszej pracy przypuszczają, że zmiany w profilu adiponektyny obserwowane w AD wynikają z mechanizmów 
kompensacyjnych przeciwstawiających się procesom neuropatologicznym, jak również z zaburzeń w zakresie homeostazy adiponektyny. 
(Endokrynol Pol 2018; 69 (5): 550–559)
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different biological activity because HMW adiponectin 
is the most active form in the peripheral blood [11]. 
Moreover, HMW adiponectin plays a role in improving 
insulin sensitivity and protecting against diabetes [11]. 
This statement was confirmed in the study of Yamauchi 
and Kadowaki, who reported that a decrease in HMW 
adiponectin concentration plays a crucial and causal 
role in obesity-linked insulin resistance and metabolic 
syndrome [12]. 
Until now, three kinds of adiponectin receptors 
have been found: AdipoR1, AdipoR2, and T-cadherin 
[13]. Several mechanisms are reported to be involved 
in AdipoRs signalling pathways. The most important 
kinase associated with adiponectin activity is AMP-
activated protein kinase (AMPK). It possesses the ability 
to regulate intracellular signalling molecules, influenc-
ing metabolic processes including insulin sensitivity, 
mitochondrial biogenesis, and oxidative metabolism. 
Furthermore, adiponectin by binding to the AdipoRs 
may also activate p38-MAPK (p38 mitogen-activated 
protein kinase) and inhibit GSK-3β (glycogen synthase 
kinase 3 beta) activity [14].
Adiponectin receptors are found in the CNS, and 
adiponectin is detectable in the cerebrospinal fluid 
(CSF) with concentrations much lower than in the pe-
ripheral blood [15]. AdipoR1 and AdipoR2 expression, 
with a predominance of AdipoR1, was found in differ-
ent brain regions, including the hypothalamus, cortex, 
hippocampus, pituitary, and area postrema [16]. The 
presence of T-cadherin in the hippocampus was also 
confirmed, suggesting an important role of adiponectin 
in the cognitive processes [17].
It has also been established that the pattern of adi-
ponectin isomers in the cerebrospinal fluid is different 
from the distribution observed in peripheral blood. 
Most CSF adiponectin are trimeric forms (approxi-
mately 80%), and the remaining are hexamers [16]. 
Adiponectin may regulate energy expenditure, 
food intake, inflammation, cell death, and protection 
in the central nervous system [18]. Considering that 
adiponectin possesses diversified activity, it could be 
hypothesised that this peptide might modulate the 
course of Alzheimer’s disease. Recently, it has been 
speculated that the reduction of adiponectin concentra-
tion or impairment of adiponectin signalling could af-
fect AD pathogenesis resulting in cognitive dysfunction 
[16]. A study performed on the animal model revealed 
that aged mice with chronic adiponectin deficiency 
had spatial memory and fear-conditioned memory 
impairments as well as anxiety. Moreover, AD-like ab-
normalities, including an enhancement of beta-amyloid 
oligomers synthesis and hyperphosphorylated tau 
protein depositions, were found in adiponectin knock-
out mice. Finally, neuroinflammation in the form of 
Introduction
Dementia is a global health and social problem. Nowa-
days, there are a growing number of demented indi-
viduals around the world. It is predicted that by the year 
2025 there will be 1.2 billion people worldwide in the 
age group 60 years and over [1]. According to the WHO, 
the total number of people with dementia is projected 
to reach 82 million by 2030. It is widely accepted that 
Alzheimer’s disease (AD) is the main cause of memory 
impairment in the elderly. Typical clinical features of 
AD include gradual memory loss, social dysfunction, 
and physical impairment. Pathological alterations in 
the brain in the course of Alzheimer’s disease consist of 
extracellular accumulation of beta-amyloid, deposits of 
pathological tau protein, inflammation, and activation 
of microglia and astrocytes [2]. Although the patho-
logical findings in the central nervous system are well 
known, all aetiological factors leading to this neurode-
generative disease have not been established yet.
In recent years, researchers have formulated several 
hypotheses about the role of metabolic disturbances in 
the development of neurodegeneration found in AD. 
The wide spectrum of metabolic abnormalities that 
could be involved in pathological changes of the central 
nervous system (CNS) include obesity and all processes 
that are connected with excess fat accumulation [1]. 
Moreover, imbalanced carbohydrate and insulin ho-
meostasis may also be correlated with pathological 
processes seen in AD brains [3]. Interestingly, it has been 
established that mid-life obesity could be a risk factor of 
AD [4]. On the other hand, fat deposits are responsible 
for unfavourable metabolic profile [5]. Indeed, obesity is 
related to diabetes, hyperlipidaemia and cardiovascular 
disease [6]. Undeniably, adipocytes are able to produce 
biologically active molecules named adipokines that 
possess multi-functional activity. Adiponectin, one 
of the adipocyte-derived substances, acts as an anti-
inflammatory and metabolism regulating factor [7]. An 
inverse correlation between adiponectin concentration 
and the amount of adipose tissue has been established. 
Additionally, adiponectin levels are reduced in obesity, 
insulin resistance, and diabetes mellitus type 2 [8]. 
Moreover, decreased levels of adiponectin have been 
associated with the presence of different kind of can-
cers [9]. Aside from fat tissue, it has been suggested 
that adiponectin could be secreted in much smaller 
amounts by other tissues [10]. In the peripheral blood 
adiponectin circulates in three main forms, which dif-
fer in the number of molecules and molecular weight. 
There are three forms of adiponectin: trimers LMW 
(low molecular weight); hexamers MMW (medium mo-
lecular weight); and multimers HMW (high molecular 
weight). In addition, these adiponectin complexes exert 
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microglial reactivation with elevated proinflammatory 
cytokines was also reported in this animal model [19]. 
In addition, the group of Kim reported that AdipoR1 
knockdown mice exhibited memory impairment and 
neuronal apoptosis, and these features were similar to 
those observed in the AD model. The authors concluded 
that AdipoR1 is an essential receptor for protecting 
against neuronal cell death and spatial and learning 
memory impairment [20]. Another group of research-
ers reported that in the APP/PS1 (amyloid precursor 
protein/presenilin 1) transgenic mice model of AD 
an altered expression of AdipoR1 and AdipoR2 in the 
hippocampus and the prefrontal cortex could be found 
[21]. Thus, the above results confirm a downregulated 
signalisation of adiponectin in the course of AD.
Also, there are metabolic alterations found in the 
central nervous system of AD subjects [22]. It has been 
reported that insulin resistance in the periphery and 
impaired carbohydrate homeostasis might be consid-
ered as a risk or even causative factor of Alzheimer’s 
disease [23]. On the other hand, there is a connection 
between peripheral levels of adiponectin and insulin 
homeostasis [24]. AD is characterised by impaired brain 
glucose uptake, reduced insulin signalling, and de-
creased insulin receptor activity in the central nervous 
system, resulting in central functional hypoglycaemia 
and hypometabolism. Insulin resistance occurring in 
the central nervous system of AD patients was named 
type 3 diabetes (T3D) [25]. 
It is very important to understand how peripheral 
metabolic impairments influence the course of AD. Thus, 
in the current study, we aimed to examine whether 
adiponectin fractions in combination with metabolic 
parameters, especially insulin and insulin resistance, 
correlate with the stage of AD.
To the best of our knowledge, this is the first time that 
all adiponectin isoforms have been investigated in AD.
Material and methods
Subjects
The study group comprised 58 women with sporadic 
Alzheimer’s disease (AD) and 40 women with normal 
cognition as the controls, matched for age and body 
mass index (BMI).
Although it is widely reported that subjects suffering 
from Alzheimer's disease lose weight in the course of 
the disease, we decided to include in our research only 
these AD individuals whose BMI did not differ from the 
BMI of the controls.
AD patients were recruited from a single medical 
centre: the Alzheimer ’s Disease Department of the 
Central Clinical Hospital of the Ministry of Interior in 
Warsaw, Poland in collaboration with the Department 
of Neurodegenerative Disorders, Mossakowski Medical 
Research Centre, Polish Academy of Science in Warsaw, 
Poland. The diagnosis of AD was based on the National 
Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria [26] 
and was in concordance with novel recommendations 
[27]. Neurological examination, neuropsychological 
assessment, and MRI (magnetic resonance imaging) 
or CT (computed tomography) scan was performed in 
AD group. To assess the severity of memory impairment 
the Mini Mental State Examination (MMSE) was carried 
out. Consequently, the AD group was divided into two 
subgroups according to the results of MMSE: moderate 
to severe stage of AD with MMSE score ≤ 15 (27 women; 
mean age 73.07 ± 4.12 years; MMSE 10.44 ± 4.32) and 
early stage of AD with MMSE score > 15 (31 women; 
mean age 74.13 ± 4.98 years; MMSE 21.32 ± 3.26).
The group of controls consisted of forty females 
(mean age 72.68 ± 7.74 years), who were healthy 
volunteers. To exclude cognitive deficits amongst the 
controls, medical examination and MMSE were per-
formed. On this basis, these individuals were found to 
be non-demented.
All participants were Caucasian, non-related females 
living in the Mazovian District in central Poland. The 
group under study comprised women only to avoid any 
sex-dependent differences in examined parameters, es-
pecially adiponectin. Exclusion criteria included chronic 
renal, liver, heart, and pulmonary dysfunction, and 
history of neoplasm. The previous history of diabetes 
also excluded individuals from the study. None of the 
examined subjects had signs of acute infections in the 
medical examination. A history of excessive alcohol 
consumption eliminated individuals from the study.
The study protocol was approved by the Ethical 
Commission of the Centre of Postgraduate Medical 
Education, Warsaw, Poland. Informed consent was 
obtained from all subjects or the patients’ caregivers.
Medical examination and anthropometric meas-
urements
All participants attended the medical examination to 
assess their health status and to collect clinical and 
anthropometric data. Height was measured with the 
use of a wall-mounted ruler. Weight was assessed using 
a digital scale. Then, BMI was calculated according to 
the formula: weight (kg) divided by height2 (m2).
Clinical data are presented in Table I.
Analytical methods
Blood samples were taken after at least six hours of 
fasting. Blood was collected in tubes containing EDTA 
and aprotinin as protease inhibitors. Immediately after 
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collection, the samples were centrifuged at 4oC and 
isolated plasma was frozen at –70°C for further analysis.
Plasma total adiponectin and HMW, MMW, and 
LMW adiponectin concentration were measured using 
a commercial ELISA Kit (ALPCO Diagnostics, Wind-
ham, NH, USA). The sensitivity of the assay was 0.019 
ng/ml. The intra-assay and inter-assay coefficients of 
variation for total adiponectin, HMW, MMW, and LMW 
were 5.4%, 5%, 10.2%, and 7.3%, respectively.
Plasma insulin concentrations were determined 
using immunoradiometric assay (DIA Source Immuno-
assay SA, Nivelles, Belgium). The detection limit was 
1 μIU/ml. Intra- and inter-assay coefficients of variation 
were 2.1% and 6.5%, respectively.
Fasting plasma glucose levels and lipid profiles were 
estimated using routine laboratory tests. Insulin resist-
ance was calculated from the results of fasting plasma 
insulin and glucose using the homeostasis model 
assessment of insulin resistance (HOMA-IR) formula: 
fasting plasma glucose (mmol/l) x fasting plasma insu-
lin concentration (µIU/ml)/22.5. Insulin resistance was 
defined as HOMA-IR > 2.5.
Statistical analyses
All statistical analyses were performed using STA-
TISTICA 10 software (StatSoft Inc., USA). 
The normality of distribution was evaluated using 
the Shapiro-Wilk test. Evaluation of the differences be-
tween groups was performed using the Kruskal-Wallis 
rank test followed by the Mann-Whitney U-test. To 
calculate the correlation coefficient between adipokines 
and anthropometric parameters as well as biochemical 
data, the Spearman test was applied. Adiponectin and 
its fractions were adjusted for BMI.
Statistical significance was accepted at p < 0.05.
Results
Basic demographic, clinical, and laboratory data of all 
subjects were calculated and are shown in Table I. Sub-
jects with Alzheimer’s disease presented significantly 
increased waist and hip measurements when compared 
to the controls (86.22 ± 10.72 cm vs. 81.90 ± 9.36 cm, 
p < 0.05 and 102.11 ± 9.75 cm vs. 98.82 ± 6.69 cm, 
p < 0.05, respectively). However, there was no difference 
in BMI between these two groups. The results of blood 
pressure measurement did not differ when AD subjects 
were compared to their non-demented counterparts.
The results of the biochemical analysis showed that 
only triglycerides (109.60 ± 43.23 mg/dl vs. 145.7 ± 80.76 
mg/dl; p < 0.01) and glucose (91.07 ± 15.05 vs. 98.15 ± 
22.74 mg/dl; p < 0.05) levels were significantly lower and 
insulin values were higher in AD subjects than in the con-
trols (11.17 ± 6.24 µIU/ml vs. 9.01 ± 8.95 µIU/ml; p < 0.05). 
No differences were found when analysing HOMA-IR.
Total adiponectin and MMW adiponectin levels 
were markedly higher in individuals with AD in com-
parison to the results of the controls (9.14 ± 3.55 µg/ml 
vs. 7.64 ± 3.56 µg/ml; p < 0.05 for total adiponectin and 
2.58 ± 1.23 µg/ml vs. 2.00 ± 1.63 µg/ml; p < 0.01 for 
MMW adiponectin, respectively). The results of HMW 
and LMW adiponectin were comparable between the 
two examined groups.
When the results of the group of Alzheimer patients 
were divided according to the stage of the disease, as 
shown in Table II, it was revealed that AD early stage 
individuals had markedly lower BMI in comparison to 
the controls (23.55 ± 3.32 kg/m2 vs. 25.02 ± 3.06 kg/m2; 
p < 0.05). When results of the waist and hip measure-
ments were compared, we found that these two param-
eters were significantly higher in women with moderate/ 
/severe AD than in the control group (88.63 ± 10.95 cm 
Table I. Anthropometric and biochemical measurements
Tabela I. Wyniki pomiarów antropometrycznych i badań 
biochemicznych
Alzheimer’s 
disease (n = 58)
Controls  
(n = 40)
p-value
Age (yrs) 73.64 ± 4.59 72.68 ± 7.74 ns
BMI [kg/m2] 24.00 ± 3.82 25.02 ± 3.06 ns
Waist [cm] 86.22 ± 10.72 81.90 ± 9.36 < 0.05
Hip [cm] 102.11 ± 9.75 98.82 ± 6.69 < 0.05
Systolic blood 
pressure [mmHg]
137.63 ± 19.48 131.50 ± 14.69 ns
Diastolic blood 
pressure [mmHg]
79.54 ± 8.11 80.63 ± 11.56 ns
MMSE 16.26 ± 6.64 > 27
Total adiponectin 
[µg/ml]
9.14 ± 3.55 7.64 ± 3.56 < 0.05
HMW adiponectin 
[µg/ml]
4.57 ± 2.19 3.87 ± 2.29 ns
MMW adiponectin 
[µg/ml)
2.58 ± 1.23 2.00 ± 1.63 < 0.01
LMW adiponectin 
[µg/ml]
1.99 ± 1.67 1.77 ± 1.31 ns
Total cholesterol 
[mg/dl]
209.12 ± 43.14 217.25 ± 49.05 ns
HDL cholesterol 
[mg/dl]
64.40 ± 16.99 58.80 ± 14.70 ns
LDL cholesterol 
[mg/dl]
117.79 ± 35.60 128.10 ± 40.52 ns
Triglycerides  
[mg/dl]
109.60 ± 43.23 145.76 ± 80.76 < 0.01
Insulin [µIU/ml] 11.17 ± 6.24 9.01 ± 8.95 < 0.05
Glucose [mg/dl] 91.07 ± 15.05 98.15 ± 22.74 < 0.05
HOMA-IR 2.57 ± 1.68 2.29 ± 2.54 ns
554
PR
A
C
E 
O
RY
G
IN
A
LN
E
Adiponectin fractions in Alzheimer’s disease Agnieszka Baranowska-Bik et al.
vs. 81.90 ± 9.36 cm, p < 0.01 for waist and 104.19 ± 10.23 cm 
vs. 98.82 ± 6.69 cm, p < 0.01 for hip measurements, 
respectively).
No differences between the groups in cholesterol 
profile were observed. However, triglyceride concentra-
tions significantly varied between some of the examined 
pools; results of both AD groups were markedly higher 
than those of the controls (115.81 ± 44.82 mg/dl vs. 145.76 
± 80.76; p < 0.05 for moderate/severe AD vs. controls 
and for 104.13 ± 41.76 mg/dl vs. 145.76 ± 80.76 mg/dl; 
p < 0.01 for early stage vs. control group, respectively).
There was a tendency for enhanced insulin levels 
in AD patients with a significant difference observed 
between individuals with advanced AD and the control 
group (12.07 ± 7.34 µIU/ml vs. 9.01 ± 8.95 µIU/ml; p < 
0.05). However, glucose concentration decreased with 
deterioration of the disease. The markedly lower values 
of glucose were found in individuals with moderate/se-
vere AD when compared to those of healthy individuals 
(89.30 ± 9.93 mg/dl vs. 98.15 ± 22.74 mg/dl; p < 0.05). 
There was a trend towards higher HOMA-IR in AD 
patients; however, the differences were non-significant.
After dividing the AD group into subgroups, we 
found that the previously observed significantly higher 
concentration of total adiponectin diminished as the dif-
ferences became non-significant. However, the trends 
remained unchanged. Moreover, there was a trend 
towards increased MMW adiponectin concentration 
with the progression of AD. Markedly higher MMW 
adiponectin concentration was observed in both sub-
populations of AD patients in comparison to the control 
group (2.67 ± 1.38 µg/ml vs. 2.00 ± 1.63 µg/ml, p < 0.05 
for moderate/ severe AD vs. controls, and 2.50 ± 1.31 
µg/ml vs. 2.00 ± 1.63 µg/ml, p < 0.05 for early stage vs. 
control group, respectively).
On the other hand, the HMW adiponectin value was 
markedly higher in AD individuals with an early stage 
of the disease when compared to the results of the con-
trols (4.90 ± 2.30 µg/ml vs. 3.87 ± 2.29 µg/ml; p < 0.05).
To avoid the role of BMI as a confounding factor in 
adiponectin assessment we adjusted the adiponectin 
profile to BMI (Table III). When the results of AD pa-
tients as the whole group were analysed, a significant 
increase in total adiponectin, and HMW and MMW 
Table II. Anthropometric and biochemical measurements after division of AD individuals into subpopulations according to 
the disease stage
Table II. Wyniki pomiarów antropometrycznych i badań biochemicznych po podziale grupy z chorobą Alzheimera w zależności 
od stadium zaawansowania choroby
Moderate to severe stage of 
AD (n = 27)
Early stage of AD (n = 31) Controls (n = 40) p-value
Age (yrs) 73.07 ± 4.12 74.13 ± 4.98 72.68 ± 7.74 ns
BMI [kg/m2] 24.53 ± 4.33 23.55 ± 3.32 25.02 ± 3.06 < 0.05c
Waist [cm] 88.63 ± 10.95 84.13 ± 10.23 81.90 ± 9.36 < 0.01b
Hip [cm] 104.19 ± 10.23 100.29 ± 9.09 98.82 ± 6.69 < 0.01b
Systolic blood pressure [mmHg] 135.81 ± 16.81 139.16 ± 21.63 131.50 ± 14.69 ns
Diastolic blood pressure [mmHg] 80.04 ± 6.37 79.13 ± 9.42 80.63 ± 11.56 ns
MMSE 10.44 ± 4.32 21.32 ± 3.26 > 27 < 0.001a
Total adiponectin [µg/ml] 9.19 ± 3.61 9.09 ± 3.56 7.64 ± 3.56 = 0.07b 
= 0.06c
HMW adiponectin [µg/ml] 4.18 ± 2.01 4.90 ± 2.30 3.87 ± 2.29 < 0.05c
MMW adiponectin [µg/ml] 2.67 ± 1.38 2.50 ± 1.31 2.00 ± 1.63 < 0.05b,c
LMW adiponectin [µg/ml] 2.34 ± 1.66 1.68 ± 1.64 1.77 ± 1.31 ns
Total cholesterol [mg/dl] 204.81 ± 37.89 212.87 ± 47.54 217.25 ± 49.05 ns
HDL cholesterol [mg/dl] 62.22 ± 16.32 66.29 ± 17.60 58.80 ± 14.70 ns
LDL cholesterol [mg/dl] 112.67 ± 27.75 122.26 ± 41.18 128.10 ± 40.52 ns
Triglycerides [mg/dl] 115.81 ± 44.82 104.13 ± 41.76 145.76 ± 80.76 < 0.05b 
< 0.01c
Insulin [µIU/ml] 12.07 ± 7.34 10.39 ± 5.10 9.01 ± 8.95 = 0.07a 
< 0.05b
Glucose [mg/dl] 89.30 ± 9.93 92.61 ± 18.42 98.15 ± 22.74 < 0.05b
HOMA-IR 2.68 ± 1.70 2.47 ± 1.69 2.29 ± 2.54 ns
amoderate and severe AD vs. early stage, bmoderate and severe AD vs. control group, cearly stage vs. control group
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fractions in AD was found when compared with the 
controls (9.14 ± 3.55 µg/ml vs. 7.64 ± 3.56 µg/ml, p < 
0.05; 4.57 ± 2.19 µg/ml vs. 3.87 ± 2.29 µg/ml, p < 0.05; 
2.58 ± 1.23 µg/ml vs. 2.00 ± 1.63 µg/ml, p < 0.01; respec-
tively). Differences in LMW adiponectin concentrations 
were non-significant.
When the subgroups of AD were singled up and the 
adiponectin array was adjusted to BMI, as presented in 
Table IV, markedly higher results of total adiponectin 
were found in advanced AD when compared to the 
results of healthy counterparts (9.19 ± 3.61 vs. 7.64 ± 
3.56 µg/ml, p < 0.05). HMW adiponectin concentration 
was significantly higher in individuals in early stages of 
the disease than in the controls (4.90 ± 2.30 µg/ml vs. 3.87 
± 2.29 µg/ml, p < 0.05). Finally, the MMW fraction level 
was highest in subjects with advanced AD and lowest 
in the controls. We revealed significant differences of 
MMW concentration between all groups in this study 
(2.67 ± 1.38 µg/ml vs. 2.50 ± 1.31 µg/ml, p < 0.01 for 
moderate/severe AD vs. early stage AD; 2.67 ± 1.38 µg/ml 
vs. 2.00 ± 1.63 µg/ml, p < 0.01 for moderate/severe AD 
vs. controls; and 2.50 ± 1.31 µg/ml vs. 2.00 ± 1.63 µg/ml, 
p < 0.01 for early stage AD vs. controls; respectively).
Correlations of adiponectin array found in the 
AD group are presented in Table V. We observed 
a positive correlation between total adiponectin and 
HDL-cholesterol (R = 0.29, p < 0.05) and a negative 
correlation between total adiponectin and HOMA-IR 
(R = –0.26, p < 0.05). MMW adiponectin correlated 
negatively with BMI (R = –0.25, p < 0.05), waist and 
hip measurements (for both parameters R = –0.27, 
p < 0.05), triglycerides (R = –0.34, p < 0.01), insu-
lin (R = –0.27, p < 0.05), and HOMA-IR (R = –0.31, 
p < 0.05). A positive correlation was found between 
MMW adiponectin and HDL-cholesterol (R = 0.36, 
p < 0.01). Only one parameter correlated with MMSE; 
we found a negative correlation between LMW adipo-
nectin and MMSE (R = –0.35, p < 0.01).
Correlation of adiponectin and its fractions con-
centration with the control group is presented in Table 
VI. In detail, in this model, as could be predicted, total 
adiponectin correlated negatively with BMI (R = –0.46, 
p < 0.01), waist (R = –0.47, p < 0.01), and hip (R = –0.48, 
p < 0.01), and positively with HDL-cholesterol (R = 0.41, 
p < 0.01). HMW adiponectin correlated similarly with 
the same parameters (BMI: R = –0.38, p < 0.05; waist: 
R = –0.35, p < 0.05; hip: R = –0.49, p < 0.01). There was 
a negative correlation between MMW fraction and 
waist measurement (R = –0.43, p < 0.01). LMW fraction 
Table III. Adiponectin profile after adjustment to BMI
Table III. Profil adiponektyny po wyłączeniu BMI jako 
czynnika zakłócającego
Alzheimer’s 
disease  
(n = 58)
Controls  
(n = 40)
p-value 
adjusted  
to BMI
Total adiponectin 
[µg/ml]
9.14 ± 3.55 7.64 ± 3.56 < 0.05
HMW adiponectin 
[µg/ml]
4.57 ± 2.19 3.87 ± 2.29 < 0.05
MMW adiponectin 
[µg/ml]
2.58 ± 1.23 2.00 ± 1.63 < 0.01
LMW adiponectin 
[µg/ml]
1.99 ± 1.67 1.77 ± 1.31 ns 
Table IV. Adiponectin profile after adjustment to BMI in AD 
subpopulations divided according to the disease stage
Table IV. Profil adiponektyny po wyłączeniu BMI jako 
czynnika zakłócającego po podziale grupy z chorobą 
Alzheimera w zależności od stadium zaawansowania choroby
Moderate to 
severe stage 
of AD (n = 27)
Early stage 
of AD 
(n = 31)
Controls 
(n = 40)
p-value 
adjusted 
to BMI
Total 
adiponectin 
[µg/ml]
9.19 ± 3.61 9.09 ± 3.56 7.64 ± 3.56 < 0.05b
HMW 
adiponectin 
[µg/ml]
4.18 ± 2.01 4.90 ± 2.30 3.87 ± 2.29 < 0.05c
MMW 
adiponectin 
[µg/ml]
2.67 ± 1.38 2.50 ± 1.31 2.00 ± 1.63 < 0.01a, b, c
LMW 
adiponectin 
[µg/ml]
2.34 ± 1.66 1.68 ± 
1.64
1.77 ± 
1.31
ns
amoderate and severe AD vs. early stage, bmoderate and severe AD vs. control 
group, cearly stage vs. control group
Table V. Correlations in AD group
Table V. Korelacje w grupie z chorobą Alzheimera
Parameter A Parameter B R p-value
Total adiponectin HDL-cholesterol 0.29 < 0.05
Total adiponectin Insulin –0.21 = 0.09
Total adiponectin HOMA-IR –0.26 < 0.05
HMW adiponectin HDL-cholesterol 0.24 = 0.06
HMW adiponectin Waist –0.23 = 0.07
MMW adiponectin BMI –0.25 < 0.05
MMW adiponectin Waist –0.27 < 0.05
MMW adiponectin Hip –0.27 < 0.05
MMW adiponectin HDL-cholesterol 0.36 < 0.01
MMW adiponectin Triglycerides –0.34 < 0.01
MMW adiponectin Insulin –0.27 < 0.05
MMW adiponectin HOMA-IR –0.31 < 0.05
LMW adiponectin MMSE –0.35 < 0.01
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correlated negatively with BMI (R = –0.42, p < 0.01) 
and hip measurement (R = –0.34, p < 0.01).
Discussion
The study focused on adiponectin levels in different 
stages of Alzheimer’s disease in correlation with the 
metabolic status of the patients. To the best of our 
knowledge, this is the first report in which the whole 
array of adiponectin forms in Alzheimer’s disease were 
evaluated. 
The effect of adiponectin on pathological processes 
in AD may have a multifactorial basis. Adiponectin en-
hances AMPK activity via AdipoR1, and, in turn, AMPK 
activation represses amyloidogenesis, decreases mTOR 
signalling, and enhances autophagy and lysosomal deg-
radation of beta-amyloid [28]. GSK-3β is recognised as 
another signalling molecule in adiponectin receptor sig-
nalling pathway [14]. It should be highlighted that GSK-β 
is involved in tau and beta-amyloid production [29], 
and it is regarded as a critical molecular link between 
two histopathological hallmarks of AD: senile plaques 
and neurofibrillary tangles [30]. Because negative 
regulation of AMPK by GSK-3β has been reported [14], 
a possible interaction between the AMPK and GSK-3β 
signalling pathways may play a role in AD. The group 
of Kadowaki revealed that adiponectin secretion is 
upregulated by PPAR-gamma (peroxisome proliferator-
activated receptor gamma) [31]. On the other hand, 
PPAR-gamma activation was found to play a role in 
amyloid clearance [32].
Anti-inflammatory properties of adiponectin may 
also have an impact on the pathological processes 
observed in AD. This peptide decreases expression of 
pro-inflammatory cytokines and increases expression of 
anti-inflammatory molecules. Furthermore, adiponectin 
is able to modulate T-cell activation and additionally 
influences the activity of natural killer cells [33]. It has 
been suggested that by decreasing IL-6 and TNF-α 
synthesis, adiponectin may indirectly affect inflamma-
tory signalling across the BBB (blood–brain barrier) and 
within the brain. Therefore, proinflammatory cytokine 
influx across the BBB might be reduced due to high 
levels of circulating adiponectin [34].
The results from the study of Ng et al. on aged mice 
confirmed a connection between chronic adiponectin 
deficiency and Alzheimer’s disease-like cognitive im-
pairments and pathologies. The main mechanisms in-
volve AMPK inactivation and cerebral insulin resistance 
[19]. Not only deficiency of adiponectin but also impair-
ment of adiponectin signalling, e.g. desensitisation of 
adiponectin receptors, might affect AD pathogenesis. 
Recently, two experimental studies supported this hy-
pothesis. Altered expression of AdipoR1 and AdipoR2 
in the hippocampus and the prefrontal cortex was 
demonstrated in transgene murine model of AD. Inter-
estingly, a weak response of these receptors to chronic 
stress was observed as well [21]. The group of Kim re-
ported that suppression of AdipoR1 promoted memory 
dysfunction and Alzheimer’s disease-like pathologies. 
In detail, AdipoR1 knockdown mice exhibited metabolic 
abnormalities and failed to perform behavioural tests 
correctly. Moreover, AdipoR1 knockdown animals were 
found to have AD-like pathologies including insulin 
signalling dysfunction, abnormal protein aggrega-
tion, and neuroinflammatory responses similar to the 
brain pathologies observed in adiponectin-knockout 
mice [20]. 
Another point that should be discussed is the BBB 
permeability and adiponectin influx to the brain. The 
peripheral adipose tissues are likely to be a major source 
of adiponectin in the CNS [35]. It has been reported that 
the trimeric and hexameric forms of adiponectin may 
enter the brain by passing through the blood–brain 
barrier [18]. Moreover, the BBB breakdown was found 
in Alzheimer ’s disease. Notably, BBB impairment 
leads to an increase of the influx of different kinds of 
substances and causes enhancement of neuronal injury, 
synaptic dysfunction, loss of neuronal connectivity, 
and neurodegeneration [36]. Thus, we presume that 
plasma adiponectin array reflects the pathological pro-
cess occurring in the CNS in the course of AD. 
We observed a marked increase in total adiponectin 
and MMW fractions in AD in comparison to the controls. 
However, when analysing the results of AD subpopula-
tions according to the stage of disease, we found a sig-
nificantly higher MMW adiponectin presence in early 
and advanced stages of disease patient subpopulations. 
Additionally, a marked increase of HMW adiponectin 
in the early stage of AD was observed in comparison to 
Table VI. Correlations in control group
Table VI. Korelacje w grupie kontrolnej
Parameter A Parameter B R p-value
Total adiponectin BMI –0.46 < 0.01
Total adiponectin Waist –0.47 < 0.01
Total adiponectin Hip –0.48 < 0.01
Total adiponectin HDL-cholesterol 0.41 < 0.01
HMW adiponectin BMI –0.38 < 0.05
HMW adiponectin Waist –0.35 < 0.05
HMW adiponectin Hip –0.49 < 0.01
HMW adiponectin HDL-cholesterol 0.42 < 0.01
MMW adiponectin Waist –0.43 < 0.01
LMW adiponectin BMI –0.42 < 0.01
LMW adiponectin Hip –0.34 < 0.01
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the control group. Furthermore, after adjustment of the 
obtained data to BMI, we revealed an enhancement of 
total adiponectin, and HMW and MMW fractions in AD 
patients with respect to the controls. It is important to 
notice that in the studied group of Alzheimer’s disease 
patients, there were no correlations observed between 
adiponectin array and markers of adiposity: BMI, and 
waist and hip measurements. Therefore, it could be 
speculated that the production of adiponectin and its 
isoforms in AD is at least partially independent of body 
mass. However, this hypothesis needs confirmation in 
further studies. 
To date, there is no expanded database concerning 
adiponectin fractions in neurodegenerative diseases 
including AD. The Kitagawa research group examined 
HMW-adiponectin as a possible factor in the devel-
opment of dementia. Results from their prospective 
research indicate that the risks of dementia in patients 
with increased and decreased HMW adiponectin levels 
were similar. The authors concluded that the level of 
HMW adiponectin in serum has no association with 
future dementia including AD [37]. In concordance 
with those results, we also did not observe a marked 
correlation between HMW adiponectin and MMSE. 
Interestingly, in individuals with Alzheimer’s disease, 
we revealed only one correlation (negative) between 
LMW adiponectin and MMSE.
Furthermore, little is known about adiponectin 
levels in the central compartment, the brain itself, 
and cerebrospinal fluid. Interestingly, the majority of 
adiponectin circulating in the CNS in healthy humans 
represents the trimer form of adiponectin [38]. This is 
in opposition to the pattern of adiponectin forms in 
the periphery [31], where the major biological acti-
vity is expressed by HMW. The total concentration of 
adiponectin in the central compartment of CSF is low 
and it is about 0.01% of the peripheral concentration, 
and it decreases in the course of AD [14, 38]. Waragai 
et al. revealed that in AD patients, CSF adiponectin 
concentration correlated positively with the MMSE 
scale. Moreover, in AD brains adiponectin was stained 
in neurofibrillary tangles, and immunoblot analysis 
showed that LMW trimer was significantly lower 
than in brains of non-demented individuals [39]. On 
the other hand, Une et al. did not show a significant 
difference in total adiponectin levels in CSF between 
AD and normal cognitive subjects, but the group of 
AD individuals was small (27 subjects) [40]. These 
results indicate that adiponectin homeostasis is pro-
bably disturbed in the brains and CSF of individuals 
suffering from AD.
There are significantly more reports concerning 
the peripheral concentrations of total adiponectin in 
AD patients. Our findings of higher total adiponectin 
concentration in the peripheral blood of AD individu-
als are in agreement with published data. The study of 
Khemka et al. confirmed that adiponectin concentration 
is elevated in individuals suffering from AD [41]. Also, 
Une et al. revealed that the level of plasma adiponec-
tin was enhanced in AD when compared with the 
controls [40]. Similarly, the group of Waragai reported 
that serum levels of adiponectin were significantly 
increased in AD patients in comparison with healthy 
controls [39]. Moreover, total adiponectin in sera in 
this study, similarly to our findings, did not correlate 
with clinical assessment of cognitive decline with use 
of MMSE [39]. Furthermore, a meta-analysis concern-
ing adiponectin in AD confirmed higher peripheral 
levels of this peptide in AD individuals with respect to 
the controls [42]. Waragai et al. hypothesised that an 
enhanced concentration of adiponectin in the course 
of AD may reflect a compensatory response to the 
abnormally reduced activity of insulin/IGF-1 receptor 
signalling pathways in AD or might instead be due to 
decreased activity of adiponectin receptor signalling 
[14]. Interestingly, results from the Framingham Heart 
Study indicate that women in whom increased total 
adiponectin levels were found had a higher risk of AD 
and all-cause dementia in comparison to those with 
adiponectin values less than the median [43].
Conversely, the results of Warren et al. did not 
reveal any significant differences in total adiponectin 
levels between AD individuals and cognitively normal 
controls. However, their studied group contained par-
ticipants of both sexes (males and females). Moreover, 
BMI significantly varied between the analysed popula-
tions [44]. Bigalke et al. also failed to find any significant 
differences in total adiponectin levels between AD 
subjects and age- and weight-matched healthy controls 
[45]. Interestingly, the group of Dukic reported that 
adiponectin concentration was not markedly different 
between AD, vascular dementia, and controls with and 
without mild cognitive impairment (MCI) [46].
In contrast, the group of Teixeira found that circulat-
ing adiponectin levels were lower in individuals with 
mild cognitive impairment, regarded as a prodromal 
stage of AD, and Alzheimer’s disease than in the non-
demented controls. Furthermore, the results of total 
adiponectin measurements did not predict a cognitive 
decline, from normal cognition to MCI or from MCI 
to AD in the follow-up [47]. Also, adiponectin results 
were reported to be independent of confounding fac-
tors including BMI and gender. Regrettably, the authors 
included individuals with diabetes mellitus and dyslipi-
daemia. Nevertheless, these medical conditions may 
negatively influence total adiponectin measurements.
Previous studies have reported the impairment of 
central and peripheral glucose and insulin homeostasis 
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in AD [25, 48, 49]. It was also established that the risk 
of AD is increased by 50–60% in individuals with type 
2 diabetes [49]. Under physiological conditions, insulin 
binds to insulin receptors that subsequently activate 
insulin receptor substrate 1 (IRS1), extracellular signal-
related kinase/mitogen-activated protein kinase, and 
PI3 kinase/Akt pathways. Moreover, insulin also inhib-
its glycogen synthase kinase-3 [50]. Improper insulin 
activity affects beta-amyloid accumulation and the 
phosphorylation of tau [29]. The results of the study by 
Ng et al. provided evidence of the relationship between 
insulin and adiponectin. The authors found in the ani-
mal model of adiponectin-knockout mice that cerebral 
insulin resistance developed in aged adiponectin-KO 
mice with attenuated AMPK activation and impaired 
insulin signalling. Furthermore, these authors, in the in 
vitro part of the experiment, revealed that adiponectin 
improved neuronal insulin activity because insulin 
sensitivity was enhanced. Finally, AdipoR1-mediated 
adiponectin activation resulted in a decrease of beta-
amyloid production, presumably through GSK3β 
inhibition [19]. 
Our research revealed enhanced insulin values in 
AD patients in comparison to the controls. However, 
we failed to find any significant differences when 
analysing HOMA-IR between the groups, but we 
found in the AD group several correlations between 
insulin and HOMA-IR, and other examined param-
eters. We reported a negative correlation between 
total adiponectin and HOMA-IR. Subsequently, MMW 
adiponectin concentration correlated negatively with 
insulin level and HOMA-IR. It should be noticed that 
participants of our study did not suffer from diabetes 
mellitus type 2.
Data of other authors are contradictory. A longi-
tudinal study from Luchsinger et al. resulted in the 
conclusion that fasting hyperinsulinaemia is a risk fac-
tor of developing AD [51] . Contrary, Van Himbergen 
et al. indicated that in the cohort of subjects from the 
Framingham Heart Study, the levels of plasma insulin, 
glucose, and glycated albumin were not associated 
with Alzheimer’s disease or all-cause dementia. On the 
other hand, Ma et al. in their meta-analysis confirmed 
an increased peripheral insulin level in subjects suffer-
ing from AD [42]. Waragai et al. observed also that in 
individuals with AD, plasma insulin and triglycerides 
were decreased and HDL and LDL cholesterol levels 
were higher than in the controls [39]. Moreover, et al. 
confirmed that insulin levels were enhanced in subjects 
diagnosed with AD [41].
Summarising, the discussed data above suggest 
that metabolically important factors, adiponectin, 
adiponectin fractions and insulin, are disturbed in the 
course of Alzheimer ’s disease. Our results indicate 
a possible link between adiponectin variations and AD. 
Also, other issues concerning the role of adiponectin 
in AD are still under discussion and further extensive 
investigation is needed.
We are aware of some limitations of our study, 
which include the size of the study group, especially 
after dividing into subgroups, or not including an 
analysis of the potential role of acetylcholinesterase 
inhibitors as hypothetical disruptors of adiponectin 
secretion. Nevertheless, the reported study is the first 
analysis of the full spectrum of adiponectin forms in 
the course of Alzheimer’s disease. We hypothesise that 
the changes in adiponectin profile observed in our AD 
group result from a compensatory mechanism against 
neuropathological processes and central adiponectin 
homeostasis impairment. Up-regulation of peripheral 
adiponectin production may result from AdipoRs dys-
function. 
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